Your browser doesn't support javascript.
loading
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.
Valgimigli, Marco; Frigoli, Enrico; Vranckx, Pascal; Ozaki, Yukio; Morice, Marie-Claude; Chevalier, Bernard; Onuma, Yoshinobu; Windecker, Stephan; Delorme, Laurent; Kala, Petr; Kedev, Sasko; Abhaichand, Rajpal K; Velchev, Vasil; Dewilde, Willem; Podolec, Jakub; Leibundgut, Gregor; Topic, Dragan; Schultz, Carl; Stankovic, Goran; Lee, Astin; Johnson, Thomas; Tonino, Pim A L; Klotzka, Aneta; Lesiak, Maciej; Lopes, Renato D; Smits, Pieter C; Heg, Dik.
Afiliação
  • Valgimigli M; Cardiocentro Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), CH-6900 Lugano, Switzerland. Electronic address: marco.valgimigli@eoc.ch.
  • Frigoli E; CTU Bern, University of Bern, Bern, Switzerland.
  • Vranckx P; Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, and Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
  • Ozaki Y; Department of Cardiology, School of Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
  • Morice MC; Cardiovascular European Research Center (CERC), and ICPS Ramsay General de santé, Massy, France.
  • Chevalier B; Ramsay Générale de Santé, Interventional Cardiology Department, Institut Cardiovasculaire Paris Sud, Massy, France.
  • Onuma Y; National University of Ireland, Galway, Ireland.
  • Windecker S; Department of Cardiology, Bern University Hospital, Bern, Switzerland.
  • Delorme L; Cardiologie et Maladies Vasculaires, AIHP-ACCAHP, Clinique du Pont De Chaume, Montauban Cedex, France.
  • Kala P; University Hospital Brno and Medical Faculty of Masaryk University, Brno, Czech Republic.
  • Kedev S; University Clinic of Cardiology, Medical Faculty, University "St. Cyril and Methodius", Skopje, Macedonia.
  • Abhaichand RK; G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, India.
  • Velchev V; Cardiology Clinic, St. Anna University Hospital Sofia, Sofia Medical University, Sofia, Bulgaria.
  • Dewilde W; Imelda Hospital, Bonheiden, Belgium.
  • Podolec J; Jagiellonian University Medical College Institute of Cardiology Department of Interventional Cardiology and the John Paul II Hospital, Krakow, Poland.
  • Leibundgut G; Cardiology, Cantonal Hospital Baselland, Liestal, Switzerland.
  • Topic D; Department of Invasive Diagnostic and Therapy, Institute for Cardiovascular Diseases "Dedinje," Belgrade, Republic of Serbia.
  • Schultz C; Department of Cardiology, Royal Perth Hospital Campus, University of Western Australia, Perth, Western Australia, Australia.
  • Stankovic G; Department of Cardiology, Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Lee A; Department of Cardiology, The Wollongong Hospital, Wollongong, New South Wales, Australia.
  • Johnson T; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Tonino PAL; Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
  • Klotzka A; 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland.
  • Lesiak M; 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland.
  • Lopes RD; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Smits PC; Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
  • Heg D; CTU Bern, University of Bern, Bern, Switzerland.
J Am Coll Cardiol ; 80(8): 766-778, 2022 08 23.
Article em En | MEDLINE | ID: mdl-35981821
BACKGROUND: Nonadherence to antiplatelet therapy after percutaneous coronary intervention (PCI) is common, even in clinical trials. OBJECTIVES: The purpose of this study was to investigate the impact of nonadherence to study protocol regimens in the MASTER DAPT (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen) trial. METHODS: At 1-month after PCI, 4,579 high bleeding risk patients were randomized to single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation [OAC]) or dual antiplatelet therapy (DAPT) for ≥2 months followed by SAPT. Coprimary outcomes included net adverse clinical events (NACE), major adverse cardiac and cerebral events (MACE), and major or clinically relevant nonmajor bleeding (MCB) at 335 days. Inverse probability-of-censoring weights were used to correct for nonadherence Academic Research Consortium type 2 or 3. RESULTS: In total, 464 (20.2%) patients in the abbreviated-treatment and 214 (9.4%) in the standard-treatment groups incurred nonadherence Academic Research Consortium type 2 or 3. At inverse probability-of-censoring weights analyses, NACE (HR: 1.01; 95% CI: 0.88-1.27) or MACE (HR: 1.07; 95% CI: 0.83-1.40) did not differ, and MCB was lower with abbreviated compared with standard treatment (HR: 0.51; 95% CI: 0.60-0.73) consistently across OAC subgroups; among OAC patients, SAPT discontinuation 6 months after PCI was associated with similar MACE and lower MCB (HR: 0.47; 95% CI: 0.22-0.99) compared with SAPT continuation. CONCLUSIONS: In the MASTER DAPT adherent population, 1-month compared with ≥3-month DAPT was associated with similar NACE or MACE and lower MCB. Among OAC patients, SAPT discontinuation after 6 months was associated with similar MACE and lower MCB than SAPT continuation (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Stents Farmacológicos / Intervenção Coronária Percutânea Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Stents Farmacológicos / Intervenção Coronária Percutânea Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article